Avaxia Biologics, Inc.
26 Pemberton Rd.
Wayland
Massachusetts
01778
United States
Website: http://www.avaxiabiologics.com/
Email: bfox@avaxiabiologics.com
23 articles about Avaxia Biologics, Inc.
-
Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation For AVX-470 For The Treatment Of Pediatric Ulcerative Colitis
11/21/2014
-
Avaxia Biologics, Inc. Reports That Lead Product AVX-470 Achieves Objectives In Phase 1b Clinical Trial In Ulcerative Colitis
5/2/2014
-
Avaxia Biologics, Inc. Awarded Patent With Broad Coverage Over Oral Anti-TNF Antibodies For Inflammatory Bowel Disease
2/11/2014
-
Avaxia Biologics, Inc. Appoints Kevin Sarney, CPA, as Vice President, Finance and Administration
10/3/2013
-
AbbVie Jumps Into $11.4 Million Series B for Avaxia Biologics, Inc.
6/7/2013
-
Avaxia Biologics, Inc. Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis
2/25/2013
-
Avaxia Biologics, Inc. Raises $6.4 Million in Series B Financing
12/18/2012
-
Avaxia Biologics, Inc. Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
11/27/2012
-
Avaxia Biologics, Inc. is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
9/18/2012
-
Avaxia Biologics, Inc. Announces Appointment of Michael D. Rivard as VP Corporate Development
6/13/2012
-
Avaxia Biologics, Inc. is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
5/23/2012
-
Avaxia Biologics, Inc. Elects Christopher Kiritsy to its Board of Directors
4/26/2012
-
Avaxia Biologics, Inc. Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
3/20/2012
-
Avaxia Biologics, Inc.'s Barbara Fox Named One of Mass High Tech's Women to Watch in 2012
3/1/2012
-
Courtagen Life Sciences, Inc. to Partner with Avaxia Biologics, Inc. in GI Acute Radiation Syndrome Initiative
2/29/2012
-
Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2/14/2012
-
Avaxia Biologics, Inc. is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease
12/13/2011
-
Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11/10/2011
-
Avaxia Biologics, Inc. Opens New Office and Labs in Lexington, Massachusetts
10/26/2011
-
Avaxia Biologics, Inc. Awarded Biomedical Advanced Research and Development Authority (BARDA) Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
8/3/2011